Evaluation of Local Anlagesia Into the Trocar Site During Operative Laparosocpy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2008 by The Baruch Padeh Medical Center, Poriya.
Recruitment status was  Not yet recruiting
Ministry of Health, Israel
Information provided by:
The Baruch Padeh Medical Center, Poriya
ClinicalTrials.gov Identifier:
First received: August 1, 2008
Last updated: February 2, 2011
Last verified: August 2008
In the literature there is conflicting data on administration of local analgesia in addition to the general anesthesia to the trocar sites during laparoscopy, We believe that adding local analgesia to the general anesthesia during laparoscopy is beneficial . the current study will evaluate prospectivly the impact of local analgesia on postoperative pain and recovery in patients undergoing operative laparoscopy

Condition Intervention
Drug: bupivacain 0.5%

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of Local Anlagesia Into the Trocar Site During Operative Laparosocpy

Resource links provided by NLM:

Further study details as provided by The Baruch Padeh Medical Center, Poriya:

Primary Outcome Measures:
  • postoperative pain measured by VAS [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • total analgesics required, patient recovery, patient satisfaction [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 120
Study Start Date: September 2010
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
preemptive trocar site analgesia
Drug: bupivacain 0.5%
trocar site injection
Other Name: marcaine
Experimental: 2
trocar site pre skin closure analgesia
Drug: bupivacain 0.5%
trocar site injection
Other Name: marcaine
No Intervention: 3

Detailed Description:
Methods: this is a blinded prospective randomized study. After approval of IRB and informed consent 120 patients undergoing for laparoscopy will be randomized after the induction of general anesthesia into three groups: Group A will receive preemptive analgesia using 3-5 cc of 0,5 % marcaine at the beginning of the procedure. Group 2 will receive a local analgesia using 3-5 cc marcaine at the end of the procedure. Group 3 will be operated under general anesthesia only. The post operative pain and patient recovery will be assessed by the nurses during the hospitalization using a VAS (Visual Analog Scale) the total analgetic drugs will be noted and after the patients discharge the patient status and satisfaction will be evaluated by phone up to 2 wks

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Female older then 18 y/o

Exclusion Criteria:

  • Allergy to marcaine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00728559

Contact: Ilan atlas, md 011972506267421 ilanatlas@yahoo.com
Contact: samer tannus, md 01197249540410 stannus@bezeqint.net

Poria Gov Hospital Not yet recruiting
Tiberias, Lower Galilee, Israel, 15208
Contact: ilan Atlas, MD    01197249080914    ilanatlas@yahoo.com   
Contact: Samer Tannus, MD    01197246652565    stannus@bezeqint.co.il   
Principal Investigator: Ilan Atlas, MD         
Sponsors and Collaborators
The Baruch Padeh Medical Center, Poriya
Ministry of Health, Israel
Study Chair: Ilan Atlas, MD Ministry of Health, Israel
  More Information

Responsible Party: Ilan Atlas, MD Gynecologic Oncology Director, Poria Medical Center
ClinicalTrials.gov Identifier: NCT00728559     History of Changes
Other Study ID Numbers: lapmar1.CTIL 
Study First Received: August 1, 2008
Last Updated: February 2, 2011
Health Authority: Israel: Ministry of Health

Keywords provided by The Baruch Padeh Medical Center, Poriya:

ClinicalTrials.gov processed this record on May 30, 2016